GSK Aims for £40 Billion Sales Target with Oncology Growth and Cost-Saving Plan
GlaxoSmithKline (GSK) has set an ambitious sales target of over £40 billion, surpassing the current consensus estimate of £36.4 billion. The company is focusing on its oncology portfolio, including antibody-drug conjugates like BLENREP and Jemperli, as key drivers for growth. GSK also announced a simplification program expected to generate £1.9 billion in savings, primarily aimed at funding pipeline investments and supporting margins amid upcoming HIV patent expirations. The CFO highlighted the importance of oncology assets such as MORES and RISRES in bridging the gap between current expectations and GSK's forecasted sales growth. The company is also preparing for potential challenges from pricing pressures on TRELEGY under U.S. inflation policies, while facing tougher comparisons with its SHINGRIX vaccine in 2027. GSK expects specialty medicines to grow significantly as a portion of the business—projecting over half by 2031—which should enhance profitability. Despite these challenges and patent expirations ahead, GSK anticipates stable or improving margins from 2028 through 2030.
Tickers: $GSK
Topics: cost savings oncology pharmaceutical pipeline investment sales targets